ProblemRetina clinics treat sight-threatening disease through a paperwork bottleneck. A 2024 JAMA Ophthalmology study found 96.2% of anti-VEGF prior auths were eventually approved, yet 59.6% still delayed care and each case took a median 100 staff minutes.
SolutionRetinaFlow is a narrow work queue for reauthorizations, drug switches, and same-week rescue cases before injection day. It builds the packet from chart data, flags missing evidence, and tells staff which cases need a human now versus later.
Market opportunityOphthalmic anti-VEGF therapy is an $18.2B market in 2025, growing to $28.6B by 2034 according to Global Market Insights. The software wedge is smaller, but sticky, because generic prior auth tools still leave retina teams juggling portals, spreadsheets, and callbacks.